Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis
- 172 Downloads
The aim of this study was to evaluate the effects of antiviral therapy on liver stiffness measurement (LSM).
Two hundred HBV patients were enrolled from four hospital centers in southern Italy; median age was 50.7 (25–75) males were 68%; 171 patients underwent to liver biopsy and 200 patients had LSM at baseline and 189 at the end of follow-up. One hundred and forty-nine patients were treated with nucleos(t)ide analogs, while 51 patients were untreated. The cutoffs of the LSM, related to the fibrosis stages, were as follows: non-advanced fibrosis ≤ 8.1 kPa and advanced fibrosis ≥ 8.2 Kpa.
At baseline, the median value of LSM was 14.1 kPa for advanced fibrosis/cirrhosis and 6.9 kPa for non-advanced fibrosis. LSM was performed at 24 months from the start of therapy. The treated patients (68% received Entecavir and 32% Tenofovir) showed a decrease in liver stiffness measurement of 1.5 kPa (p < 0.001) in non-advanced fibrosis and of 6 kPa (p < 0.001) in advanced fibrosis/cirrhosis. In the patients not undergoing antiviral treatment, no statistically significant change of the LSM was observed (p = 0.26). A logistic binary regression model showed that the only independent factor associated with a significant change in the LSM was the liver stiffness value at baseline (odd ratio 2.855; 95% CI 1.456–5.788; (p = 0.007).
Long-term antiviral therapy induced a significant reduction of liver stiffness measurement and this result may be related to the reduction of liver fibrosis.
KeywordsTransient elastography Liver stiffness Hepatic fibrosis Chronic hepatitis B Antiviral therapy
AITF (Italian Association of Liver Transplanted Patients)—Delegation of Caserta (Italy) and Stefania Milione MD, Università degli Studi della Campania “Luigi Vanvitelli”, for the cooperation in editorial assistance.
Financial support, Progetto SATTE—Campania Region (DGR 1389/2009).
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
- 4.Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label followup study. Lancet. 2013;381:468–75. https://doi.org/10.1016/s0140-6736(12)61425-1.CrossRefPubMedGoogle Scholar
- 5.Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, Beebe S, Xu D, Tang H, Iloeje U. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274–6. https://doi.org/10.1016/j.cgh.2010.11.040.CrossRefPubMedGoogle Scholar
- 11.Kettaneh A, Marcellin P, Douvin C, Poupon R, Ziol M, Beaugrand M, de Lédinghen V. Features associated with success rate and performance of Fibroscan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol. 2007;46:628–34. https://doi.org/10.1016/j.jhep.2006.11.010.CrossRefPubMedGoogle Scholar
- 13.Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208. https://doi.org/10.1002/hep.2462.CrossRefPubMedGoogle Scholar
- 14.Rinaldi L, Restivo L, Guerrera B, Zampino R, Marrone A, Pasquale G, Zappalà R, Nevola R, Adinolfi LE. Hepatic steatosis and necro-inflammatory activity overestimate liver stiffness by Transient Elastography in staging liver fibrosis in chronic hepatitis C. J Hepat Res. 2014;3:01–6.Google Scholar
- 18.Boursier J, Zarski JP, de Ledinghen V, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Calès P. Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–91. https://doi.org/10.1002/hep.25993.CrossRefPubMedGoogle Scholar
- 24.Cai YJ, Dong JJ, Wang XD, Huang SS, Chen RC, Chen Y, Wang YQ, Song M, Chen YP, Li Z, Zhou MT, Shi KQ. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B. J Viral Hepat. 2017;24:1005–15. https://doi.org/10.1111/jvh.12715.CrossRefPubMedGoogle Scholar
- 25.Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol. 2013;28:1842–8. https://doi.org/10.1111/jgh.12327.CrossRefPubMedGoogle Scholar
- 26.Castéra L, Bernard PH, Bail B, Foucher J, Trimoulet P, Merrouche W, Couzigou P, Lédinghen V. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 2011;33:455–65. https://doi.org/10.1111/j.1365-2036.2010.04547.x.CrossRefPubMedGoogle Scholar
- 27.Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–93. https://doi.org/10.1002/hep.23785.CrossRefPubMedGoogle Scholar
- 28.Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103:2776–83. https://doi.org/10.1111/j.1572-0241.2008.02086.x.CrossRefPubMedGoogle Scholar
- 32.Andersen ES, Weiland O, Leutscher P, Krarup H, Westin J, Moessner B, Konopski Z, Frigstad SO, Kjær M, Christensen PB, Weis N. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scand J Gastroenterol. 2011;46:760–6. https://doi.org/10.3109/00365521.2011.565068.CrossRefPubMedGoogle Scholar
- 36.Jang W, Yu SI, Sinn DH, Park SH, Park H, Park JY, Jeon TJ, Oh TH, Shin WC, Choi WC. Longitudinal change of liver stiffness by transient elastography in chronic hepatitis B patients treated with nucleos(t)ide analogue. Clin Res Hepatol Gastroenterol. 2014;38:195–200. https://doi.org/10.1016/j.clinre.2013.10.003.CrossRefPubMedGoogle Scholar
- 39.Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, Asselah T, Boyer N, Lada O, Castelnau C, Martinot-Peignoux M, Valla DC, Bedossa P, Marcellin P. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012;32:612–21. https://doi.org/10.1111/j.14783231.2011.02660.x.CrossRefPubMedGoogle Scholar
- 41.Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109:1241–9. https://doi.org/10.1038/ajg.2014.157.CrossRefPubMedGoogle Scholar
- 42.Warren-Gash C, Childs K, Thornton A, Bhagani S, Demma S, Srivastava A, Leen C, Agarwal K, Rodger AJ, Sabin CA, Joint UK. CHIC and liver transplant advisory group. Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. Infection. 2017;45:215–20. https://doi.org/10.1007/s15010-016-0976-x.CrossRefPubMedPubMedCentralGoogle Scholar